The List of Adverse Reactions To The Jab And The Coverup For Mid-Terms

A newly released document featuring data pertaining to adverse reactions following a round of Pfizer’s Covid-19 inoculations has been making rounds on the internet. No wonder all we hear about is the Ukraine right now. The bill is coming due for forcing the jab on too many people.

But of course the MSM has moved on and will now carry the water for Biden, Fauci and Psaki who told us that we had to have the jab and that it WOULD stop Covid-19, that it was safe and effective, prevent you from dying and prevent the trasnmission of Covid to others. All of what they told us was lies.

Oh, and it doesn’t work on 5-11 year olds.


Details of the document were damning, revealing a massive number of observed adverse reactions beginning on page 30. The list is exhaustive, continuing seemingly endlessly until its conclusion about 8 pages later.It appears that much of the information in the document was hidden from the public in the past, with a blurb on the first page explaining that “dissemination of this information outside of Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited.”The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.5.3.6-postmarketing-experience-1Download
The number of adverse events listed remained numerous. One notable condition found in Pfizer’s data is 1p36 deletion syndrome, which the National Library of Medicine describes as “a disorder that typically causes severe intellectual disability.” They also point out the severity of the disease, noting that “most affected individuals do not speak, or speak only a few words” and “may have temper tantrums, bite themselves, or exhibit other behavior problems.”
The “Adverse Events of Special Interest” identified from pages 30-38 can be found below:

1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5’nucleotidase increased;Acousticneuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epilepticaphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acuteencephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilicdermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acutehaemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acutemotor axonal neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardialinfarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison’sdisease;Administration site thrombosis;Administration site vasculitis;Adrenalthrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Airembolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholicseizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmunehepatitis;Alopecia areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammoniaincreased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloidarthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylacticshock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoidshock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathicneuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine receptor antibodypositive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal gangliaantibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibodypositive;Anti-erythrocyte antibody positive;Anti-exosome complex antibody positive;Anti-GAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibodypositive;Antigliadin antibody positive;Anti-glomerular basement membrane antibodypositive;Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibodypositive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibodyincreased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased;Anti-insulin receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibodypositive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-musclespecific kinase antibody positive;Anti-myelin-associated glycoprotein antibodiespositive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardialantibody positive;Anti-neuronal antibody positive;Antineutrophil cytoplasmic antibodyincreased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmicantibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibodyincreased;Antinuclear antibody positive;Antiphospholipid antibodiespositive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombinantibody positive;Antiribosomal P antibody positive;Anti-RNA polymerase III antibodypositive;Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibodypositive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibodypositive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;Anti-VGKC antibody positive;Anti-vimentin antibody positive;Antiviral prophylaxis;Antiviraltreatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aorticthrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application sitethrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypassthrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft sitestenosis;Arteriovenous graft thrombosis;Arteritis;ArteritisPage 30090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000083BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 2coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinusthrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferaseincreased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio indexincreased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID-19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypicalbenign partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmuneanaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blisteringdisease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinatingdisease;Autoimmune dermatitis;Autoimmune disorder;Autoimmuneencephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eyedisorder;Autoimmune haemolytic anaemia;Autoimmune heparin-inducedthrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmunehypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmunelymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmunenephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmunepancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmuneretinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmuneuveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatismepileptic;Autonomic nervous system imbalance;Autonomic seizure;Axialspondyloarthritis;Axillary vein thrombosis;Axonal and demyelinatingpolyneuropathy;Axonal neuropathy;Bacterascites;Baltic myoclonic epilepsy;Bandsensation;Basedow’s disease;Basilar artery thrombosis;Basophilopenia;B-cellaplasia;Behcet’s syndrome;Benign ethnic neutropenia;Benign familial neonatalconvulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoproteinantibody positive;Bickerstaff’s encephalitis;Bile output abnormal;Bile outputdecreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugatedincreased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshotchorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphataseincreased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugatedincreased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressuredecreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toesyndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stemthrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitismycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;Budd-Chiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calciumembolism;Capillaritis;Caplan’s syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiacfailure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenicshock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratoryarrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterialembolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter sitevasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cementembolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar arterythrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebralartery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebralmicroembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinusthrombosis;Cerebral venous thrombosis;Cerebrospinal thromboticPage 31090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000084BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 3tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;Child-Pugh-Turcotte score abnormal;Child-Pugh-Turcotte scoreincreased;Chillblains;Choking;Choking sensation;Cholangitis sclerosing;Chronicautoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatiguesyndrome;Chronic gastritis;Chronic inflammatory demyelinatingpolyradiculoneuropathy;Chronic lymphocytic inflammation with pontine perivascularenhancement responsive to steroids;Chronic recurrent multifocal osteomyelitis;Chronicrespiratory failure;Chronic spontaneous urticaria;Circulatory collapse;Circumoraloedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliacdisease;Cogan’s syndrome;Cold agglutinins positive;Cold type haemolyticanaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagendisorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complementfactor C4 decreased;Complement factor decreased;Computerised tomogram liverabnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylviansyndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenitalvaricella infection;Congestive hepatopathy;Convulsion in childhood;Convulsionslocal;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary arterydisease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypassthrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirustest positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranialnerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CRESTsyndrome;Crohn’s disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal bandpresent;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneoussarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokinerelease syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acuteinflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosispostoperative;Deficiency of bile secretion;Deja vu;Demyelinatingpolyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitisherpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetesmellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membranereaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminatedintravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminatedneonatal herpes simplex;Disseminated varicella;Disseminated varicella zoster vaccine virusinfection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortexsyndrome;Double stranded DNA antibody positive;Dreamy state;Dressler’s syndrome;Dropattacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy withburst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Emboliccerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolicstroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitisallergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitishaemorrhagic;Encephalitis periaxialis diffusa;Encephalitis postimmunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrineophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacterpneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;EosinophilicPage 32090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000085BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 4fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilicoesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonicseizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythemamultiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disabilitystatus scale score decreased;Expanded disability status scale score increased;Exposure tocommunicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eyeswelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonicseizure;Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrileneutropenia;Felty’s syndrome;Femoral artery embolism;Fibrillaryglomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focaldyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetorhepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetesmellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity testdecreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferaseincreased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onsetnon-motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpessimplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritismembranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidlyprogressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiencysyndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2gangliosidosis;Goodpasture’s syndrome;Graftthrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis withpolyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;Guillain-Barre syndrome;Haemolytic anaemia;Haemophagocyticlymphohistiocytosis;Haemorrhage;Haemorrhagic ascites;Haemorrhagicdisorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagicvasculitis;Hantavirus pulmonary infection;Hashimoto’sencephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;Henoch-Schonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-inducedthrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flowdecreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzymedecreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosismarker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatichypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepaticpain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascularthrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressuregradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scanabnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esteraseinhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpesophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplexcervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpessimplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpessimplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplexoesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplexpneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplexviraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virusPage 33090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000086BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 5infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infectionneurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zostermeningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotisingretinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zosterreactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne’s syndrome;Humanherpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infectionreactivation;Human herpesvirus 7 infection;Human herpesvirus 8infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemiabenign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivityvasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;Hypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossalnerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensivecrisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathicneutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerveparalysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immune-mediated adverse reaction;Immune-mediated cholangitis;Immune-mediatedcholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediatedencephalopathy;Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immune-mediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immune-mediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediatedmyocarditis;Immune-mediated myositis;Immune-mediated nephritis;Immune-mediatedneuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediatedrenal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion bodymyositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infectivethrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion sitevasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillationsite thrombosis;Insulin autoimmune syndrome;Interstitial granulomatousdermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranialpressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsicfactor antibody positive;IPEX syndrome;Irregular breathing;IRVAN syndrome;IVth nerveparalysis;IVth nerve paresis;JC polyomavirus test positive;JC virus CSF test positive;Jeavonssyndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathicarthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriaticarthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokinesyndrome;Kawasaki’s disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosis-prone diabetes mellitus;Kounis syndrome;Lafora’s myoclonic epilepsy;Lambl’sexcrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoidarthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LEcells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidaseincreased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenianeonatal;Lewis-Sumner syndrome;Lhermitte’s sign;Lichen planopilaris;Lichen planus;Lichensclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver functiontest abnormal;Liver function test decreased;Liver function test increased;Liverinduration;Liver injury;Liver iron concentration abnormal;Liver iron concentrationPage 34090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000087BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 6increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Livertenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratorytract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepaticcirrhosis;Lupus cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupushepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupuspleurisy;Lupus pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytichypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC syndrome;Magneticresonance imaging liver abnormal;Magnetic resonance proton density fat fractionmeasurement;Mahler sign;Manufacturing laboratory analytical testing issue;Manufacturingmaterials issue;Manufacturing production issue;Marburg’s variant multiplesclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocyticenterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medicaldevice site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitisherpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitisherpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV testpositive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesentericartery thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastaticcutaneous Crohn’s disease;Metastatic pulmonaryembolism;Microangiopathy;Microembolism;Microscopic polyangiitis;Middle Eastrespiratory syndrome;Migraine-triggered seizure;Miliary pneumonia;Miller Fishersyndrome;Mitochondrial aspartate aminotransferase increased;Mixed connective tissuedisease;Model for end stage liver disease score abnormal;Model for end stage liver diseasescore increased;Molar ratio of total branched-chain amino acid to tyrosine;Molybdenumcofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathymultiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocalmotor neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosisrelapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisysteminflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myastheniagravis crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitistransverse;Myocardial infarction;Myocarditis;Myocarditis post infection;Myoclonicepilepsy;Myoclonic epilepsy and ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasalherpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn’s disease;Neonatalepileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpessimplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemicfibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudorelapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronalneuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosasyndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenianeonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodularvasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfectiveencephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupationalexposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocularhyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocularvasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepaticdisease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmicherpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;OpticPage 35090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000088BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 7neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngealoedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelinationsyndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmuneneuropsychiatric disorders associated with streptococcal infection;Paget-Schroettersyndrome;Palindromic rheumatism;Palisaded neutrophilic granulomatousdermatitis;Palmoplantar keratoderma;Palpablepurpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous pneumonia;Paradoxicalembolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplasticdermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranialnerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partialseizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venousthrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditislupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral arterythrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombusextension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid proteindecreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit malepilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformisacuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumoniaadenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumoniainfluenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumoniaparainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMSsyndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmunesyndrome type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmunesyndrome type III;Polyglandular disorder;Polymicrogyria;Polymyalgiarheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portalpyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressureincreased;Portal vein thrombosis;Portosplenomesenteric venous thrombosis;Post proceduralhypotension;Post procedural pneumonia;Post procedural pulmonary embolism;Post strokeepilepsy;Post stroke seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viralfatigue syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictalstate;Postoperative respiratory distress;Postoperative respiratory failure;Postoperativethrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomysyndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Precerebralartery thrombosis;Pre-eclampsia;Preictal state;Premature labour;Prematuremenopause;Primary amyloidosis;Primary biliary cholangitis;Primary progressive multiplesclerosis;Procedural shock;Proctitis herpes;Proctitis ulcerative;Product availabilityissue;Product distribution issue;Product supply issue;Progressive facialhemiatrophy;Progressive multifocal leukoencephalopathy;Progressive multiplesclerosis;Progressive relapsing multiple sclerosis;Prosthetic cardiac valvethrombosis;Pruritus;Pruritus allergic;Pseudovasculitis;Psoriasis;Psoriaticarthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonaryembolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonaryoil microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonarysepsis;Pulmonary thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonaryvasculitis;Pulmonary veno-occlusive disease;Pulmonary venous thrombosis;Pyodermagangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation leukopenia;RadiculitisPage 36090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000089BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 8brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussenencephalitis;Raynaud’s phenomenon;Reactive capillary endothelial proliferation;Relapsingmultiple sclerosis;Relapsing-remitting multiple sclerosis;Renal amyloidosis;Renalarteritis;Renal artery thrombosis;Renal embolism;Renal failure;Renal vascularthrombosis;Renal vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratoryarrest;Respiratory disorder;Respiratory distress;Respiratory failure;Respiratoryparalysis;Respiratory syncytial virus bronchiolitis;Respiratory syncytial virusbronchitis;Retinal artery embolism;Retinal artery occlusion;Retinal artery thrombosis;Retinalvascular thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal vein thrombosis;Retinolbinding protein decreased;Retinopathy;Retrograde portal vein flow;Retroperitonealfibrosis;Reversible airways obstruction;Reynold’s syndrome;Rheumatic braindisease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor increased;Rheumatoidfactor positive;Rheumatoid factor quantitative increased;Rheumatoid lung;Rheumatoidneutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule removal;Rheumatoidscleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHOsyndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 testpositive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2antibody test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARS-CoV-2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARS-CoV-2 test positive;SARS-CoV-2 viraemia;Satoyoshisyndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associateddigital ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondaryamyloidosis;Secondary cerebellar degeneration;Secondary progressive multiplesclerosis;Segmented hyalinising vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizurelike phenomena;Seizure prophylaxis;Sensation of foreign body;Septic embolus;Septicpulmonary embolism;Severe acute respiratory syndrome;Severe myoclonic epilepsy ofinfancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt thrombosis;Silentthyroiditis;Simple partial seizures;Sjogren’s syndrome;Skin swelling;SLE arthritis;Smoothmuscle antibody positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenicartery thrombosis;Splenic embolism;Splenic thrombosis;Splenic veinthrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-inducedthrombocytopenia syndrome;Status epilepticus;Stevens-Johnson syndrome;Stiff legsyndrome;Stiff person syndrome;Stillbirth;Still’s disease;Stoma site thrombosis;Stoma sitevasculitis;Stress cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacuteendocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian arteryembolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplaineddeath in epilepsy;Superior sagittal sinus thrombosis;Susac’s syndrome;Suspected COVID-19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympatheticophthalmia;Systemic lupus erythematosus;Systemic lupus erythematosus disease activityindex abnormal;Systemic lupus erythematosus disease activity index decreased;Systemiclupus erythematosus disease activity index increased;Systemic lupus erythematosusrash;Systemic scleroderma;Systemic sclerosispulmonary;Tachycardia;Tachypnoea;Takayasu’s arteritis;Temporal lobe epilepsy;Terminalileitis;Testicular autoimmunity;Throat tightness;Thromboangiitisobliterans;Thrombocytopenia;Thrombocytopenicpurpura;Thrombophlebitis;Thrombophlebitis migrans;ThrombophlebitisPage 37090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)FDA-CBER-2021-5683-0000090BNT162b25.3.6 Cumulative Analysis of Post-authorization Adverse Event ReportsCONFIDENTIALPage 9neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibodypositive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosismesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thromboticstroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulatingimmunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongueoedema;Tonic clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bileacids increased;Toxic epidermal necrolysis;Toxic leukoencephalopathy;Toxic oilsyndrome;Tracheal obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitismycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminasesincreased;Transfusion-related alloimmune neutropenia;Transient epilepticamnesia;Transverse sinus thrombosis;Trigeminal nerve paresis;Trigeminalneuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous sclerosiscomplex;Tubulointerstitial nephritis and uveitis syndrome;Tumefactive multiplesclerosis;Tumour embolism;Tumour thrombosis;Type 1 diabetes mellitus;Type Ihypersensitivity;Type III immune complex mediated reaction;Uhthoff’sphenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cordthrombosis;Uncinate fits;Undifferentiated connective tissue disease;Upper airwayobstruction;Urine bilirubin increased;Urobilinogen urine decreased;Urobilinogen urineincreased;Urticaria;Urticaria papular;Urticarial vasculitis;Uterinerupture;Uveitis;Vaccination site thrombosis;Vaccination site vasculitis;Vagus nerveparalysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella zostergastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zostersepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascularpseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculiticrash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cavaembolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venousthrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosisneonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venousthrombosis;VIth nerve paralysis;VIth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cordparesis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;Whitenipple sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young’s syndrome;Zika virusassociated Guillain Barre syndrome.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.